another review paper on nitrosamines, with a regulatory interest. N-Nitrosamine: An Update on the Chemistry of Generation, Causes and Mitigation Strategies in Pharmaceuticals | Pharmaceutical Chemistry Journal | Springer Nature Link
abstract
N-Nitrosamines are a class of chemical compounds with nitroso and amine moieties and a well-known potential risk of developing cancer. The presence of this impurity in drugs has raised concerns regarding the safety profile and usage of many drugs, including valsartan, ranitidine, nizatidine, metformin, and the antitubercular drugs rifampicin and rifapentine, which have also led to the recall and shortage of these drugs. The current review provides information about various alerts and safety concerns raised by regulatory authorities worldwide because of the presence of N-nitrosamine contamination in pharmaceuticals. This review covers several factors and the mechanisms involved in the generation of N-nitrosamine from various active pharmaceutical ingredients (APIs) and drug products (DPs) via effective mitigation strategies. This article also focuses on several initiatives taken by regulatory authorities and official pharmacopoeias after the emergence of N-nitrosamine impurities in pharmaceuticals in 2018 for the control of these mutagenic impurities in APIs and DPs. The current article covers various analytical methods provided by several regulatory authorities that are sensitive enough to detect and estimate these impurities. Analytical methods are necessary for the estimation of N-nitrosamine in pharmaceuticals to control it effectively.